Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - ENANTA PHARMACEUTICALS INC | enta-ex311_10.htm |
| EX-10.18 - EX-10.18 - ENANTA PHARMACEUTICALS INC | enta-ex1018_1136.htm |
| EX-4.3 - EX-4.3 - ENANTA PHARMACEUTICALS INC | enta-ex43_1302.htm |
| 10-K - 10-K - ENANTA PHARMACEUTICALS INC | enta-10k_20170930.htm |
| EX-32.1 - EX-32.1 - ENANTA PHARMACEUTICALS INC | enta-ex321_9.htm |
| EX-31.2 - EX-31.2 - ENANTA PHARMACEUTICALS INC | enta-ex312_8.htm |
| EX-21.1 - EX-21.1 - ENANTA PHARMACEUTICALS INC | enta-ex211_12.htm |
| EX-10.19 - EX-10.19 - ENANTA PHARMACEUTICALS INC | enta-ex1019_1137.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-189217, 333-192935, 333-202257, 333-209542 and 333-215011) of Enanta Pharmaceuticals, Inc. of our report dated December 11, 2017 relating to the financial statements, which appears in this Form 10-K.
|
/s/ PricewaterhouseCoopers LLP |
|
Boston, Massachusetts |
|
December 11, 2017 |